American Journal of Cardiology
Volume 102, Issue 9, Supplement , Pages 4J-11J , 3 November 2008

Assessing the Landscape of Stent Thrombosis: The Drug-Eluting Versus Bare-Metal Stent Controversy

  • David G. Rizik, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: David G. Rizik, MD, Scottsdale Healthcare Hospitals, Suite A 100, 9755 North 90th Street, Scottsdale, Arizona 85258
    • ,
  • Kevin J. Klassen, MD

References 

  1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501
  2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
  3. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, et al Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945–2951
  4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  6. FDA Clinical Overview for Panel Packet, DES Thrombosis Panel, December 7-8, 2006. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4253b1_01.pdfAccessed March 19, 2008
  7. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  8. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  9. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  10. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effecktivitats Trial (BASKET). Lancet. 2005;366:921–929
  11. Camenzind E, Nordman AJ, Briel M, Bucher HC. Safety of drug-eluting stents: insights from meta analysis. Presented at the European Society of Cardiology Annual Congress; September 2-6 2006;Barcelona, Spain. Hotline I; 707009
  12. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784–2814
  13. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, et al Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116:745–754
  14. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation. 2008;117:261–295
  15. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3445 patients followed for up to 3 years. J Am Coll Cardiol. 2007;49:1043–1051
  16. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation. 2007;115:813–818
  17. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  18. Spaulding C, Daeman J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  19. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38–42
  20. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788–794
  21. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA. 2005;294:1215–1223
  22. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306–3313
  23. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  24. Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099
  25. Schampaert E, Cohen EA, Schlüter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110–1115
  26. Stone GW. DES Evidence-based medicine perspectives on emerging safety concerns, real world outcomes and use recommendations. Presented at the Transcatheter Cardiovascular Therapeutics 18th Annual Scientific Symposium; October 22–27 2006;Washington, DC
  27. Leon MB. An evidence-based medicine appraisal of clinical indications for drug-eluting stents—appropriate use, abuse, and uncertainties. Presented at the Transcatheter Cardiovascular Therapeutics 18th Annual Scientific Symposium; October 22–27 2006;Washington, DC
  28. Kandzari DE. Contemporary PCI with the CYPHER stent: the standard of care and comparison. Presented at the British Cardiovascular Intervention Society, Advanced Angioplasty 2007 http://www.bcis.org.uk/resources/presentations/aa2007Accessed March 19, 2008
  29. Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, et al A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1381–1385
  30. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, et al A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342–352

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)01492-6

doi: 10.1016/j.amjcard.2008.09.003

American Journal of Cardiology
Volume 102, Issue 9, Supplement , Pages 4J-11J , 3 November 2008

Article Tools

* Image Usage & Resolution